{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:39Z","timestamp":1792787979132,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCI","award":["P30CA042014-23"],"award-info":[{"award-number":["P30CA042014-23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      A majority of patients undergoing curative intent surgery for pancreatic ductal adenocarcinoma (PDAC) will unfortunately develop recurrent disease. Treatment outcomes for patients with metastatic disease remain suboptimal. In this study, we evaluated clinical outcomes of patients with recurrent PDAC who received systemic therapy and compared outcomes to patients with\n                      <jats:italic>de novo<\/jats:italic>\n                      metastatic PDAC undergoing systemic therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients diagnosed with metastatic PDAC between 2014 and 2019 were included using a real-world database. Patients were characterized as either\n                      <jats:italic>de novo<\/jats:italic>\n                      or recurrent based on the date of metastatic diagnosis and history of surgical resection. Overall survival (OS) was summarized within groups via Kaplan\u2013Meier survival estimates and compared using Cox proportional hazards models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 5170 patients with metastatic PDAC, of which 1101 (21.3%) were classified as having recurrent disease. Median OS for the recurrent group was significantly greater at 10.8\u00a0m (95% CI 9.9\u201311.7) than in the\n                      <jats:italic>de novo<\/jats:italic>\n                      group at 7.3\u00a0m (95% CI 7.0\u20137.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). We did not observe a significant difference in OS based on when patients recurred after surgery: 10.0\u00a0m (95% CI 8.7\u201311) within six months of surgery versus 11.6\u00a0m (95% CI 10\u201312,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.256) greater than six months from surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These data support the inclusion of patients with recurrent PDAC in clinical trials for advanced disease, including those who develop recurrent disease within six months of surgery. Due to observed differences in survival, randomization should be stratified by disease presentation (recurrent vs\n                      <jats:italic>de novo<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-022-10130-4","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:02:51Z","timestamp":1665540171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study"],"prefix":"10.1186","volume":"22","author":[{"given":"Laura","family":"Miotke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nevala-Plagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Florou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garrido-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"10130_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022. https:\/\/doi.org\/10.3322\/caac.21708","DOI":"10.3322\/caac.21708"},{"issue":"11","key":"10130_CR2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1136\/gutjnl-2014-308653","volume":"64","author":"J Yu","year":"2015","unstructured":"Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64(11):1783. https:\/\/doi.org\/10.1136\/gutjnl-2014-308653.","journal-title":"Gut"},{"key":"10130_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1304369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013. https:\/\/doi.org\/10.1056\/nejmoa1304369.","journal-title":"N Engl J Med"},{"key":"10130_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1011923","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011. https:\/\/doi.org\/10.1056\/nejmoa1011923.","journal-title":"N Engl J Med"},{"key":"10130_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809775","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/nejmoa1809775.","journal-title":"N Engl J Med"},{"key":"10130_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32409-6","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017. https:\/\/doi.org\/10.1016\/S0140-6736(16)32409-6.","journal-title":"Lancet"},{"issue":"14","key":"10130_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 2013;310(14):1473. https:\/\/doi.org\/10.1001\/jama.2013.279201.","journal-title":"JAMA"},{"key":"10130_CR8","doi-asserted-by":"publisher","unstructured":"Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2020;38(15_suppl). https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.4505","DOI":"10.1200\/JCO.2020.38.15_suppl.4505"},{"issue":"6","key":"10130_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","volume":"3","author":"M Reni","year":"2018","unstructured":"Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413. https:\/\/doi.org\/10.1016\/S2468-1253(18)30081-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1\u20132","key":"10130_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2011.12.021","volume":"148","author":"DA Tuveson","year":"2012","unstructured":"Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012;148(1\u20132):21. https:\/\/doi.org\/10.1016\/j.cell.2011.12.021.","journal-title":"Cell"},{"issue":"1\u20132","key":"10130_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","volume":"148","author":"AD Rhim","year":"2012","unstructured":"Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1\u20132):349. https:\/\/doi.org\/10.1016\/j.cell.2011.11.025.","journal-title":"Cell"},{"issue":"1\u20132","key":"10130_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","volume":"148","author":"H Haeno","year":"2012","unstructured":"Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1\u20132):362. https:\/\/doi.org\/10.1016\/j.cell.2011.11.060.","journal-title":"Cell"},{"key":"10130_CR13","doi-asserted-by":"publisher","unstructured":"Sakamoto H, Attiyeh MA, Gerold JM, et al. The evolutionary origins of recurrent pancreatic cancer. Cancer Discov. 2020;10(6). https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1508","DOI":"10.1158\/2159-8290.CD-19-1508"},{"issue":"16","key":"10130_CR14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763. https:\/\/doi.org\/10.1200\/JCO.19.02274.","journal-title":"J Clin Oncol"},{"key":"10130_CR15","doi-asserted-by":"publisher","unstructured":"Gbolahan OB, Tong Y, Sehdev A, O\u2019neil B, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/s12885-019-5630-4","DOI":"10.1186\/s12885-019-5630-4"},{"key":"10130_CR16","volume-title":"Testing the use of the usual chemotherapy before and after surgery for removable pancreatic cancer","author":"NCT04340141","year":"2020","unstructured":"NCT04340141. Testing the use of the usual chemotherapy before and after surgery for removable pancreatic cancer. 2020. https:\/\/clinicaltrials.gov\/show\/NCT04340141."},{"key":"10130_CR17","doi-asserted-by":"publisher","unstructured":"Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine\/nab-paclitaxel (Gem\/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38(15_suppl). https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.4504","DOI":"10.1200\/jco.2020.38.15_suppl.4504"},{"key":"10130_CR18","doi-asserted-by":"publisher","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.16.20037143","DOI":"10.1101\/2020.03.16.20037143"},{"key":"10130_CR19","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. 2020."},{"issue":"6","key":"10130_CR20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/1475-6773.13669","volume":"56","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Gossai A, Monroe S, Nussbaum NC, Parrinello CM. Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States. Health Serv Res. 2021;56(6):1281. https:\/\/doi.org\/10.1111\/1475-6773.13669.","journal-title":"Health Serv Res"},{"issue":"8","key":"10130_CR21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/cancers13081776","volume":"13","author":"S Sivakumar","year":"2021","unstructured":"Sivakumar S, Abu-Shah E, Ahern DJ, et al. Activated regulatory t-cells, dysfunctional and senescent t-cells hinder the immunity in pancreatic cancer. Cancers (Basel). 2021;13(8):1776. https:\/\/doi.org\/10.3390\/cancers13081776.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10130_CR22","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.21037\/jgo-21-55","volume":"12","author":"HC Gits","year":"2021","unstructured":"Gits HC, Tang AH, Harmsen WS, et al. Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. J Gastrointest Oncol. 2021;12(5):2275. https:\/\/doi.org\/10.21037\/jgo-21-55.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"10130_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/bjc.2013.32","volume":"108","author":"Y Ino","year":"2013","unstructured":"Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914. https:\/\/doi.org\/10.1038\/bjc.2013.32.","journal-title":"Br J Cancer"},{"key":"10130_CR24","doi-asserted-by":"publisher","unstructured":"Matrisian LM, Berlin JD. The past, present, and future of pancreatic cancer clinical trials. Am Soc Clin Oncol Educ B. 2016;(36). https:\/\/doi.org\/10.1200\/edbk_159117","DOI":"10.1200\/edbk_159117"},{"issue":"6","key":"10130_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/COC.0000000000000807","volume":"44","author":"CE Guerra","year":"2021","unstructured":"Guerra CE, Kelly S, Redlinger C, Hern\u00e1ndez P, Glanz K. Pancreatic cancer clinical treatment trials accrual a closer look at participation rates. Am J Clin Oncol Cancer Clin Trials. 2021;44(6):227. https:\/\/doi.org\/10.1097\/COC.0000000000000807.","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"10130_CR26","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1200\/JCO.2013.49.4823","volume":"31","author":"WA Hoos","year":"2013","unstructured":"Hoos WA, James PM, Rahib L, Talley AW, Fleshman JM, Matrisian LM. Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol. 2013;31:3432. https:\/\/doi.org\/10.1200\/JCO.2013.49.4823.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10130-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:03:13Z","timestamp":1665540193000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10130-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10130"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10130-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board (IRB) approval of the study protocol was obtained before the study was conducted and included a waiver of informed consent. IRB name and registration number: WCG IRB; IRB00000533. All methods were performed in accordance with the ethical guidelines and regulations for human data research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ben Haaland consults for the National Kidney Foundation and Value Analytics Labs. He has also received travel funds from Flatiron Health. The other authors have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1054"}}